Combination pharmacotherapy for the treatment of neuropathic pain in adults: systematic review and meta-analysis

被引:42
作者
Balanaser, Marielle [1 ]
Carley, Meg [1 ]
Baron, Ralf [2 ]
Finnerup, Nanna B. [3 ]
Moore, R. Andrew [4 ]
Rowbotham, Michael C. [5 ]
Chaparro, Luis E. [6 ]
Gilron, Ian [1 ,7 ,8 ,9 ,10 ]
机构
[1] Queens Univ, Dept Anesthesiol & Perioperat Med, Kingston, ON, Canada
[2] Univ Hosp Schleswig Holstein, Dept Neurol, Div Neurol Pain Res & Therapy, Campus Kiel, Kiel, Germany
[3] Aarhus Univ, Danish Pain Res Ctr, Dept Clin Med, Aarhus, Denmark
[4] Newton Ferrers, Plymouth, England
[5] Univ Calif San Francisco, Pain Management Ctr, Sch Med, San Francisco, CA USA
[6] Grand River Hosp, Dept Anesthesia, Kitchener, ON, Canada
[7] Queens Univ, Ctr Neurosci Studies, Dept Biomed Sci, Kingston, ON, Canada
[8] Queens Univ, Ctr Neurosci Studies, Dept Mol Sci, Kingston, ON, Canada
[9] Queens Univ, Sch Policy Studies, Kingston, ON, Canada
[10] Queens Univ, Kingston Gen Hosp, Dept Anesthesiol & Perioperat Med, Kingston, ON K7L 2V7, Canada
基金
加拿大健康研究院;
关键词
DOUBLE-BLIND; DIABETIC-NEUROPATHY; CANCER PAIN; TOPICAL AMITRIPTYLINE; SYMPTOMATIC TREATMENT; PLACEBO; PREGABALIN; MANAGEMENT; KETAMINE; EFFICACY;
D O I
10.1097/j.pain.0000000000002688
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Neuropathic pain causes substantial morbidity and healthcare utilization. Monotherapy with antidepressants or anticonvulsants often fails to provide relief. Combining different drugs sometimes provides improved analgesia and/or tolerability. More than half of patients receive 2 or more analgesics, and combination trials continue to emerge. This review comprehensively searched CENTRAL, MEDLINE, and EMBASE for relevant trials. Included studies are double-blind randomized controlled trials evaluating combinations of 2 or more drugs vs placebo or at least one monotherapy in adults with neuropathic pain. Outcomes included measures of efficacy and adverse effects. Risk of bias was assessed. Meta-analyses compared combination to monotherapy wherever 2 or more similar studies were available. Forty studies (4741 participants) were included. Studies were heterogenous with respect to various characteristics, including dose titration methods and administration (ie, simultaneous vs sequential) of the combination. Few combinations involved a nonsedating drug, and several methodological problems were identified. For opioid-antidepressant, opioid-gabapentinoid, and gabapentinoid-antidepressant combinations, meta-analyses failed to demonstrate superiority over both monotherapies. In general, adverse event profiles were not substantially different for combination therapy compared with monotherapy. Despite widespread use and a growing number of trials, convincing evidence has not yet emerged to suggest superiority of any combination over its respective monotherapies. Therefore, implementing combination therapy-as second- or third-line treatment-in situations where monotherapy is insufficient, should involve closely monitored individual dosing trials to confirm safety and overall added benefit. Further research is needed, including trials of combinations involving nonsedating agents, and to identify clinical settings and specific combinations that safely provide added benefit.
引用
收藏
页码:230 / 251
页数:22
相关论文
共 72 条
  • [1] Thalamic Deep Brain Stimulation for Neuropathic Pain: Efficacy at Three Years' Follow-Up
    Abreu, Vasco
    Vaz, Rui
    Rebelo, Virginia
    Rosas, Maria Jose
    Chamadoira, Clara
    Gillies, Martin J.
    Aziz, Tipu Z.
    Pereira, Erlick A. C.
    [J]. NEUROMODULATION, 2017, 20 (05): : 504 - 513
  • [2] Management of diabetic neuropathy by sodium valproate and glyceryl trinitrate spray: A prospective double-blind randomized placebo-controlled study
    Agrawal, R. P.
    Goswami, Jitender
    Jain, Shreyans
    Kochar, D. K.
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2009, 83 (03) : 371 - 378
  • [3] Amr YM, 2010, PAIN PHYSICIAN, V13, P245
  • [4] [Anonymous], 2011, BMJ-BRIT MED J, V343, pd5928, DOI DOI 10.1136/BMJ.D5928
  • [5] An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A
    Attarian, Shahram
    Vallat, Jean-Michel
    Magy, Laurent
    Funalot, Benoit
    Gonnaud, Pierre-Marie
    Lacour, Arnaud
    Pereon, Yann
    Dubourg, Odile
    Pouget, Jean
    Micallef, Joelle
    Franques, Jerome
    Lefebvre, Marie-Noelle
    Ghorab, Karima
    Al-Moussawi, Mahmoud
    Tiffreau, Vincent
    Preudhomme, Marguerite
    Magot, Armelle
    Leclair-Visonneau, Laurene
    Stojkovic, Tanya
    Bossi, Laura
    Lehert, Philippe
    Gilbert, Walter
    Bertrand, Viviane
    Mandel, Jonas
    Milet, Aude
    Hajj, Rodolphe
    Boudiaf, Lamia
    Scart-Gres, Catherine
    Nabirotchkin, Serguei
    Guedj, Mickael
    Chumakov, Ilya
    Cohen, Daniel
    [J]. ORPHANET JOURNAL OF RARE DISEASES, 2014, 9
  • [6] Effectiveness and Safety of Tapentadol Prolonged Release (PR) Versus a Combination of Tapentadol PR and Pregabalin for the Management of Severe, Chronic Low Back Pain With a Neuropathic Component: A Randomized, Double-blind, Phase 3b Study
    Baron, Ralf
    Martin-Mola, Emilio
    Mueller, Matthias
    Dubois, Cecile
    Falke, Dietmar
    Steigerwald, Ilona
    [J]. PAIN PRACTICE, 2015, 15 (05) : 455 - 470
  • [7] A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA
    Barton, Debra L.
    Wos, Edward J.
    Qin, Rui
    Mattar, Bassam I.
    Green, Nathan Benjamin
    Lanier, Keith S.
    Bearden, James Dewitt, III
    Kugler, John W.
    Hoff, Kay L.
    Reddy, Pavan S.
    Rowland, Kendrith M., Jr.
    Riepl, Mike
    Christensen, Bradley
    Loprinzi, Charles L.
    [J]. SUPPORTIVE CARE IN CANCER, 2011, 19 (06) : 833 - 841
  • [8] Clinical characteristics and patterns of healthcare utilization in patients with painful neuropathic disorders in UK general practice: a retrospective cohort study
    Berger, Ariel
    Sadosky, Alesia
    Dukes, Ellen
    Edelsberg, John
    Oster, Gerry
    [J]. BMC NEUROLOGY, 2012, 12
  • [9] Gabapentin for neuropathic cancer pain: A randomized controlled trial from the gabapentin cancer pain study group
    Caraceni, A
    Zecca, E
    Bonezzi, C
    Arcuri, E
    Tur, RY
    Maltoni, M
    Visentin, M
    Gorni, G
    Martini, C
    Tirelli, W
    Barbieri, M
    De Conno, F
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 2909 - 2917
  • [10] Combination pharmacotherapy for the treatment of neuropathic pain in adults
    Chaparro, Luis Enrique
    Wiffen, Philip J.
    Moore, R. Andrew
    Gilron, Ian
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2012, (07):